Welcome to our dedicated page for Apptly Health Technologies news (Ticker: ESVNF), a resource for investors and traders seeking the latest updates and insights on Apptly Health Technologies stock.
UBERDOC Health Technologies Corp. operates a direct-pay healthcare marketplace that connects patients with physicians and specialists at transparent, upfront prices. Company news centers on its specialty-care platform, direct-access healthcare model, employer-benefits positioning, and developments tied to public-market operations.
Recurring updates also cover the company's completed amalgamation with ROV Investment Partners, its transition from the former Serra Energy Metals issuer profile, Canadian Securities Exchange and Frankfurt trading references, market-making arrangements, capital-structure actions, and board governance changes.
Apptly Health Technologies (ESVNF) began trading on the OTCQB Venture Market in the United States under symbol ESVNF, effective September 2, 2026. The company’s common shares are now DTC eligible for electronic clearing and settlement, and it continues to trade on the CSE under symbol APPT. Apptly states that the OTCQB listing and DTC eligibility are expected to enhance liquidity and visibility among US investors as it expands its shareholder base.
Apptly Health Technologies (CSE: APPT, FSE: 4KL), operator of the UberDoc direct-pay healthcare marketplace, announced a strategic partnership with Koning, maker of the FDA-approved Koning Vera Breast CT, to expand patient access to non-compression 3D breast imaging.
Under the agreement, Koning will display UberDoc physician and service listings on its platform and introduce its provider sites to UberDoc, while Apptly will supply physician and service data plus trackable links so patients can move from Koning’s platform directly into UberDoc to find and book appointments at transparent, upfront prices. The initial term is twelve months with automatic one-year renewals. The parties intend to negotiate a revenue-sharing arrangement in a separate amendment; Apptly has not attributed any revenue to the agreement and gives no assurance that such an arrangement will be concluded.
Apptly Health Technologies (CSE: APPT, FSE: 4KL) plans a non-brokered private placement of up to 8,000,000 units at $0.125 per unit, for gross proceeds of up to $1,000,000. Each unit includes one common share and one warrant exercisable at $0.25 for 12 months.
Warrants may be accelerated if Apptly’s share price equals or exceeds $0.35 on the CSE for 30 consecutive trading days. Net proceeds are expected to be used primarily for general working capital. The securities will be subject to a four-month-and-one-day hold period under Canadian securities laws.
Apptly Health Technologies (CSE: APPT, FSE: 4KL0), operator of the UberDoc direct-pay healthcare marketplace, announced a strategic partnership with Bryleos, a woman-owned life sciences company focused on NAD+ science and oral cellular-health formulations. Bryleos will join the UberDoc marketplace with a dedicated presence, giving patients and physicians direct access to its offerings.
According to Apptly, the partnership supports its broader platform strategy by extending UberDoc’s direct, transparent-access model beyond specialist care and adding another potential revenue stream. Bryleos contributes its patent-pending LathMized® NAD+ platform and states that its work is grounded in randomized, placebo-controlled human research published in peer-reviewed journals. Apptly notes UberDoc does not provide medical advice and that clinical decisions remain between patients and physicians.
Apptly Health Technologies (CSE: APPT, FSE: 4KL, OTC: ESVNF), operator of the UberDoc direct-pay healthcare marketplace, appointed four physicians to its Advisory Board: Dr. Eric Bricker, Dr. Diana Girnita, Dr. Cristin Dickerson, and Dr. Fred Liss.
Their backgrounds span healthcare finance, direct-pay specialty care, employer-sponsored healthcare, and physician-led organizations, which Apptly expects will support expansion of its nationwide direct-pay marketplace, physician network, and employer and hospital relationships.
Apptly Health (CSE: APPT, OTC: ESVNF), operator of UberDoc, signed a three-year Strategic Collaboration Agreement with Emphera Health effective July 1, 2026. UberDoc supplies direct-pay consultation and booking technology while Emphera manages outpatient clinical and surgical services.
The deal includes profit-sharing mechanisms, should add about 2,000 specialists to UberDoc, expanding its network from 5,000 to over 7,000, and targets self-funded employers, leveraging Emphera contracts that serve a total addressable population of more than 40 million people.
Apptly Health Technologies (CSE: APPT, OTC: ESVNF), operator of the UberDoc direct-pay healthcare marketplace, appointed Lemonaid Health co-founder Paul Johnson to its advisory board as it scales nationwide.
The company also changed its name from UberDoc Health Technologies, maintained ticker APPT, and engaged Focus Communications for C$60,000 in investor relations services.
UBERDOC Health Technologies Corp. (CSE: APPT, FSE: 4KL0) plans to change its corporate name to Apptly Health Technologies Corp. around June 23, 2026, subject to approvals.
The rebrand reflects its evolution into a direct-pay healthcare marketplace built on a 5,000+ physician network across 55+ specialties, with no change to share count, rights, or operations. Director Sean Kearney resigned June 9, 2026.
UBERDOC Health Technologies (ESVNF) appointed John Dvor to its Board of Directors as it scales its nationwide direct-pay specialty care marketplace and expands strategic partnerships.
Dvor brings experience in healthcare technology, therapeutics, and venture leadership. UberDoc’s platform includes over 5,000 board-certified specialists across all 50 states.
UberDoc Health Technologies (ESVNF) announced a leadership transition as the company enters its next growth phase. Former CEO Sean Kearney has departed, and founder Dr. Paula Muto has been appointed Interim CEO effective May 15, 2026.
According to UberDoc, Kearney helped guide listings on the Canadian and Frankfurt exchanges and strengthen operations. Dr. Muto, a board-certified vascular surgeon, will focus on expanding the physician network and accelerating consumer adoption while the Board conducts a permanent CEO search.